Novo details new strategy in obesity, other disease areas

Novo CEO Mike Doustdar Novo Nordisk By Andrew Joseph

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.

LONDON — Novo Nordisk on Monday sought to assure investors that it would regain its momentum in the coming years, outlining plans to expand its pipeline and find new products that it could sell more like consumer goods than traditional medicines, building off what’s occurring with its obesity treatments.